A Phase 1 interventional study of Bosentan and Placebo in Diabetes Mellitus, sponsored by Retinset SL. Completed at 2 sites in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-16.
Sponsored by Retinset SL · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.
Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 200th largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2019, is one of 2 in phase 1, and was the 186th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:
Eduardo Luis Martín Javier · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Brazil and 8 more countries
Ages 18+
Universidad Complutense de Madrid · Sites in Spain
Ages 18–65
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 18+
Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Sites in Spain
Ages 20–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
254 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 24 · Phase 3 97 · Phase 4 27
First in 1994; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 394 across the 211 interventional studies, 512 across the 42 observational. Of the 193 that completed or were terminated, 89 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
145 of 254 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Retinset SL as lead sponsor.
Retinset SL has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
6 of the studies in Diabetes Mellitus with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05769868Phase 3Consorcio Centro de Investigación Biomédica en Red (CIBER)Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments | 2027-03 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT05243368Maimónides Biomedical Research Institute of CórdobaEvaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics | 2026-12-30 |
| NCT07463456Eduardo Luis Martín JavierInter-Device Concordance of Plantar Thermal Asymmetry Measurement (HIK-DM-2026) | 2027-04 |
| NCT07285330Consorci Sanitari de l'Alt Penedès i GarrafDietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 254 studies in Diabetes Mellitus with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety of topical Bosentan in Type II Diabetes patients
The study is a Phase I, masked, placebo controlled clinical trial to assess safety of topical Bosentan in Type II Diabetes patients with no diabetes retinopathy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
Drug: Bosentan
The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
Drug: Placebo
Eyedrop
Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
Epitheliopathy
Presence of epitheliopathy in the cornea or conjunctiva
Time frame: 1 month
Presence of ocular discomfort
Presence of ocular discomfort assessed with Ocular Surface Disease Index (OSDI) questionnaire
Time frame: 1 month
Anterior segment inflammation
Presence of any sign of clinically significant inflammation at anterior segment
Time frame: 1 month
Ran from Sep 2019 to primary completion in May 2022, 32 months.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 32 months is above that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan